Topic: drug development

The congress connects experimental and clinical pharmacology, from identifying therapeutic targets and testing mechanisms in preclinical models to clinical trials, access to treatment and evidence from routine care. Its programme examines synaptic and cellular communication in neurodegeneration, immunometabolism, inflammation, oncology, precision medicine and sex-aware experimental design. Sessions also address drug development, regulatory decisions, artificial intelligence and the sustainability of pharmacological research. Plenary lectures connect unmet needs in oncology to improved care and

Carolyn Bertozzi explains why sugars on cell surfaces matter for communication between cells and how new chemical methods make these complex molecules accessible to research. The discussion connects this work to neuroscience, biological aging and drug development.

Daphne Koller of insitro discusses the differences between finding predictive patterns and identifying interventions that improve disease outcomes. The conversation examines biological data scarcity, structure and causality, failures in drug development and the limits of speeding up wet-lab work with AI agents. It also considers foundation models for biology, generalization beyond observed data, human evidence and scientific discovery. Hosted by Ravid Shwartz Ziv and Allen Roush. Watch the full conversation on the publisher’s YouTube channel.

The World Health Organization (WHO) estimates that untreated mental disorders accountfor 13% of the total global burden of disease, and by 2030, depression alone will be the leadingcause of disability around the world – outpacing heart disease, cancer, and HIV. This grim pictureis further compounded by the mental health burden delivered by the coronavirus pandemic.The lack of novel treatment options in psychiatry is restricted by a limited understanding in theneuroscience basis of mental disorders, availability of relevant biomarkers, poor predictability inanimal models, and high failure rates